MilliporeSigma Wins INTERPHEX Exhibitor Award for Best Technological Innovation
MilliporeSigma today announced that its Millistak+® HC Pro portfolio has won an INTERPHEX Exhibitor Award for Best Technological Innovation.
- Award recognizes new, fully synthetic clarification filter
- Millistak+® HC Pro portfolio of depth filters improves capacity, reducing footprint by up to 2x for primary clarification
Burlington, Massachusetts, April 18, 2018 – MilliporeSigma today announced that its Millistak+® HC Pro portfolio has won an INTERPHEX Exhibitor Award for Best Technological Innovation.
“MilliporeSigma is dedicated to delivering innovations that bring advanced drug therapies to market, faster,” said Andrew Bulpin, head of Process Solutions at MilliporeSigma. “As the first fully synthetic depth filters, MilliporeSigma’s Millistak+® HC Pro portfolio provides as much as twice the filtration capacity as commercial diatomaceous earth (DE)-based benchmarks and offers customers greater productivity and speed with reduced risk. We are honored to be recognized for this advancement in biopharmaceutical manufacturing.”
MilliporeSigma’s Millistak+® HC Pro portfolio is a family of synthetic depth filters providing cleaner, more consistent depth filtration media than other DE- and cellulose-based filter offerings. Made with entirely synthetic materials, Millistak+® HC Pro filters eliminate naturally derived components from the clarification process, resulting in increased productivity with less flushing.
MilliporeSigma’s Process Solutions business unit provides the industry’s most comprehensive portfolio of high-quality products and services for biopharmaceutical manufacturing.
For biopharmaceutical manufacturers, MilliporeSigma’s depth filter reduces total organic carbon extractables and pre-use flush volume by 50 percent. The filter also eliminates the potential for beta glucans, which can interfere with limulus amebocyte lysate testing used to detect and quantify bacterial endotoxins. The unparalleled lot-to-lot consistency helps biopharmaceutical manufacturers design a more robust clarification process.
MilliporeSigma is showcasing this industry-leading portfolio at Booth 2841 at INTERPHEX, which runs through tomorrow at the Javits Center, New York City.
For more information on MilliporeSigma’ Millistak+® HC Pro, visit www.emdmillipore.com/Millistak+HCPro.
All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to http://www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 20,000 employees and 60 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.
Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.
Merck KGaA, Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has five businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Life Science and Performance Materials – and generated sales of €15.3 billion in 2017. Almost 53,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.
Merck KGaA, Darmstadt, Germany is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. The company holds the global rights to the name and the trademark “Merck” internationally except for the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Merck KGaA, Darmstadt, Germany Highlights Commitment to Improving Cancer Outcomes ...
Merck KGaA, Darmstadt, Germany, announced 43 abstracts covering modalities and mechanisms will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, Chicago, Ill., US.